Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Amicus Therapeutics (FOLD) Misses Q1 EPS by 25c
May 8, 2019 7:23 AM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.56), $0.25 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $34 million versus the consensus estimate of $37.86 million.
GUIDANCE:
2019 Financial Guidance
For the full-year 2019 the Company anticipates total Galafold... More
